Insulin Lispro
drugOn this page
Also known as HumalogIns humalogInsulin lispro sanofiInsulina lisproInsuline lisproLiprologLyumjevLyumjev (previously liumjev)
Summary
Insulin Lispro (CHEMBL1201538) is an approved protein (ATC A10AB04); indicated across 4 conditions including diabetes mellitus and hyperglycemia.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- ATC class: A10AB04 (+1 more)
- Indications: 4 conditions
- Clinical trials: 146
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201538 |
| Name | Insulin Lispro |
| Type | Protein |
| Max phase | 4 |
| ATC | A10AB04, A10AC04 |
Also known as: Humalog, Ins humalog, Insulin lispro, Insulin lispro sanofi, Insulina lispro, Insuline lispro, Liprolog, Lyumjev, Lyumjev (previously liumjev), INSULIN LISPRO
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
4 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| diabetes mellitus | 4 | MONDO:0005015 | EFO:0000400 |
| hyperglycemia | 3 | MONDO:0002909 | HP:0003074 |
| type 1 diabetes mellitus | 3 | MONDO:0005147 | MONDO:0005147 |
| type 2 diabetes mellitus | 3 | MONDO:0005148 | MONDO:0005148 |
Clinical trials
Total trials: 146.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 47 |
| PHASE3 | 41 |
| PHASE4 | 23 |
| Not specified | 16 |
| PHASE2 | 15 |
| PHASE2/PHASE3 | 2 |
| PHASE1/PHASE2 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07109245 | PHASE4 | RECRUITING | Do Antipsychotics Block Insulin Action in the Brain: is it a Class Effect? |
| NCT00191282 | PHASE4 | COMPLETED | Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes |
| NCT00461331 | PHASE4 | COMPLETED | Comparison of Insulins Aspart and Lispro in Insulin Pumps |
| NCT00548808 | PHASE4 | COMPLETED | A Study for Type 2 Diabetic Patients |
| NCT00607087 | PHASE4 | COMPLETED | Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus |
| NCT00985712 | PHASE4 | COMPLETED | A Study on the Effect of 2 Pen Devices on HbA1c |
| NCT01175811 | PHASE4 | COMPLETED | A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus |
| NCT01215955 | PHASE4 | COMPLETED | Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes |
| NCT01526733 | PHASE4 | COMPLETED | Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase |
| NCT01613807 | PHASE4 | COMPLETED | Humalog® Mix50/50(tm) as a Treatment for Gestational Diabetes |
| NCT01773473 | PHASE4 | COMPLETED | Comparison of Insulin Mix25 Versus Mix50 |
| NCT01848990 | PHASE4 | COMPLETED | CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM) |
| NCT01971047 | PHASE4 | WITHDRAWN | Safety and Efficacy Study of Correcting Hyperglycemia in Patients With Diabetes Having Out-patient Surgery |
| NCT02189395 | PHASE4 | TERMINATED | Comparison of Neutral Protamine Hagedorn (NPH) and Lantus Based Insulin Regimen in the Management of Hypoglycemia in the Hospitalized Patients in Noncritical Care Setting |
| NCT02250794 | PHASE4 | WITHDRAWN | Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit |
| NCT02276859 | PHASE4 | COMPLETED | Normal Versus Dual Wave Insulin Bolus for High-protein Food |
| NCT02526810 | PHASE4 | UNKNOWN | Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes |
| NCT02685449 | PHASE4 | UNKNOWN | Insulin Requirement for Pure-protein Meal in Children With Type 1 Diabetes on Insulin Pumps. |
| NCT03328845 | PHASE4 | COMPLETED | Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study) |
| NCT03509324 | PHASE4 | COMPLETED | Effectiveness of Glucose Control, β Cell Function in Response to Short-term Insulin Pump Therapy in Type 2 Diabetes |
| NCT03660553 | PHASE4 | TERMINATED | Simplified Insulin Regimen for the Elderly |
| NCT04019821 | PHASE4 | COMPLETED | Super-Bolus: Effects on Postprandial Glycemia After High Glycemic Index Meal |
| NCT04124302 | PHASE4 | COMPLETED | The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal. |
| NCT06931041 | PHASE3 | ACTIVE_NOT_RECRUITING | Comparing Efficacy of Autologous Serum Eye Drops With and Without Insulin in Autoimmune Dry Eye: A Randomized Clinical Trial |
| NCT00071448 | PHASE3 | COMPLETED | Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population |
| NCT00097071 | PHASE3 | COMPLETED | Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents |
| NCT00115570 | PHASE3 | COMPLETED | Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents |
| NCT00348374 | PHASE3 | COMPLETED | Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes |
| NCT00666718 | PHASE3 | COMPLETED | A Comparison Study of Basal Bolus Therapies Together With Lispro Insulin in Type 2 Diabetes Patients |
| NCT00700622 | PHASE3 | TERMINATED | Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks |
| NCT00849576 | PHASE3 | COMPLETED | Effect of Treatment With Insulin VIAjectTM Compared to Regular Human Insulin and Insulin Lispro on Mealtime Blood Vessel Stress in Patients With Type 2 Diabetes Mellitus. |
| NCT00960661 | PHASE3 | COMPLETED | A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes |
| NCT00993473 | PHASE3 | COMPLETED | 6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes |
| NCT01023165 | PHASE3 | UNKNOWN | Effects of Intensive Bolus Intravenous Insulin Delivery on Metabolic Integrity in Type 1 and Type 2 Diabetes |
| NCT01109316 | PHASE3 | COMPLETED | Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use |
| NCT01134107 | PHASE3 | COMPLETED | Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use |
| NCT01136746 | PHASE3 | TERMINATED | Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin |
| NCT01191268 | PHASE3 | COMPLETED | A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4) |
| NCT01398670 | PHASE3 | WITHDRAWN | Immunogenicity Study of Wockhardt’s Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics |
| NCT01421147 | PHASE3 | COMPLETED | A Study in Adults With Type 1 Diabetes |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).